福森药业(01652.HK)拟斥6000万元收购永丰康德医药51%股权
格隆汇7月14日丨福森药业(01652.HK)公布,2019年7月12日,公司全资附属衡盛投资,拟向菏泽市牡丹区华瀚网络信息技术中心收购目标公司江西永丰康德医药有限公司51%股权,收购代价人民币6000万元。
公告显示,目标公司主要从事进出口中药材、中药饮片、中成药、化学原料药、药用赋形剂、抗生素原料药物、生化药物及相关技术。目标公司现时进口并向中国市场出售名为Kefadim的药品(化学名称:注射用头孢他啶)。2018年全年,目标公司实现收益人民币8094.5万元,税后净利润82.4万元。
根据收购协议,目标公司将取得商标及权利,即名为Kefadim的药物的两项商标、已取得的所有先前研发成果的权利、所有技术及生产权利以及由此产生利益的权利。目标公司原拥有人及卖方已保证商标及权利将容许目标公司合法生产及销售Kefadim并享有由此产生的所有权利及利益,而转让方(为独立第三方)将出具不竞争契据,表明其不会进行任何与Kefadim有关的任何制造、销售及经营活动。
因此,董事会认为收购事项为集团参与制造及销售Kefadim的良机,可拓阔集团的制造及销售药品业务及多元化其收入来源。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.